TAMPA, Fla., Oct. 14 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today preliminary results from a pivotal anterior uveitis trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback